help button home button Am J Pathol Underwater digital camera with your antibody orders
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/ajpath.2008.071074 on June 5, 2008

Published online before print June 5, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ajpath.2008.071074v1
173/1/265    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Halin, C.
Right arrow Articles by Detmar, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Halin, C.
Right arrow Articles by Detmar, M.
(American Journal of Pathology. 2008;173:265-277.)
© 2008 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2008.071074

Inhibition of Chronic and Acute Skin Inflammation by Treatment with a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

Cornelia Halin*, Hermann Fahrngruber{dagger}, Josef G. Meingassner{dagger}, Guido Bold{ddagger}, Amanda Littlewood-Evans{ddagger}, Anton Stuetz{dagger} and Michael Detmar*

From the Institute of Pharmaceutical Sciences,* Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland; Novartis Institutes for BioMedical Research,{dagger} Vienna, Austria, and Novartis Institutes for BioMedical Research,{ddagger} and Basel, Switzerland

Although vascular remodeling is a hallmark of many chronic inflammatory disorders, antivascular strategies to treat these conditions have received little attention to date. We investigated the effects of a newly identified vascular endothelial growth factor (VEGF) receptor tyrosine-kinase inhibitor, NVP-BAW2881, on endothelial cell function in vitro and its anti-inflammatory activity in different animal models. NVP-BAW2881 inhibited proliferation, migration, and tube formation by human umbilical vein endothelial cells and lymphatic endothelial cells in vitro. In a transgenic mouse model of psoriasis, NVP-BAW2881 reduced the number of blood and lymphatic vessels and infiltrating leukocytes in the skin, and normalized the epidermal architecture. NVP-BAW2881 also displayed strong anti-inflammatory effects in models of acute inflammation; pretreatment with topical NVP-BAW2881 significantly inhibited VEGF-A-induced vascular permeability in the skin of pigs and mice. Furthermore, topical application of NVP-BAW2881 reduced the inflammatory response elicited in pig skin by UV-B irradiation or by contact hypersensitivity reactions. These results demonstrate for the first time that VEGF receptor tyrosine-kinase inhibitors might be used to treat patients with inflammatory skin disorders such as psoriasis.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society for Investigative Pathology.